Howden BP - Search Results

1

Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial.

Tong SYC, Lye DC, Yahav D, Sud A, Robinson JO, Nelson J, Archuleta S, Roberts MA, Cass A, Paterson DL, Foo H, Paul M, Guy SD, Tramontana AR, Walls GB, McBride S, Bak N, Ghosh N, Rogers BA, Ralph AP, Davies J, Ferguson PE, Dotel R, McKew GL, Gray TJ, Holmes NE, Smith S, Warner MS, Kalimuddin S, Young BE, Runnegar N, Andresen DN, Anagnostou NA, Johnson SA, Chatfield MD, Cheng AC, Fowler VG Jr, Howden BP, Meagher N, Price DJ, van Hal SJ, O'Sullivan MVN, Davis JS; Australasian Society for Infectious Diseases Clinical Research Network. Tong SYC, et al. Among authors: howden bp. JAMA. 2020 Feb 11;323(6):527-537. doi: 10.1001/jama.2020.0103. JAMA. 2020. PMID: 32044943 Free PMC article. Clinical Trial.

2

Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.

Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Charles PG, et al. Among authors: howden bp. Clin Infect Dis. 2004 Feb 1;38(3):448-51. doi: 10.1086/381093. Epub 2004 Jan 12. Clin Infect Dis. 2004. PMID: 14727222

3

Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility.

Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, Grabsch EA, Roberts SA, Robson J, Read K, Bak N, Hurley J, Johnson PD, Morris AJ, Mayall BC, Grayson ML. Howden BP, et al. Clin Infect Dis. 2004 Feb 15;38(4):521-8. doi: 10.1086/381202. Epub 2004 Jan 29. Clin Infect Dis. 2004. PMID: 14765345

4

Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus.

Howden BP, Grayson ML. Howden BP, et al. Clin Infect Dis. 2006 Feb 1;42(3):394-400. doi: 10.1086/499365. Epub 2005 Dec 15. Clin Infect Dis. 2006. PMID: 16392088 Review.

5

Cutaneous zygomycosis caused by Saksenaea vasiformis following water-related wound in a 24-year-old immunocompetent woman.

Stewardson AJ, Holmes NE, Ellis DH, Howden BP. Stewardson AJ, et al. Among authors: howden bp. Mycoses. 2009 Nov;52(6):547-9. doi: 10.1111/j.1439-0507.2008.01648.x. Epub 2009 Aug 3. Mycoses. 2009. PMID: 19682315

6

Treating Gram-positive infections: vancomycin update and the whys, wherefores and evidence base for continuous infusion of anti-Gram-positive antibiotics.

Chua K, Howden BP. Chua K, et al. Among authors: howden bp. Curr Opin Infect Dis. 2009 Dec;22(6):525-34. doi: 10.1097/QCO.0b013e328331fbcd. Curr Opin Infect Dis. 2009. PMID: 19738465 Review.

7

Two novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection.

Gao W, Chua K, Davies JK, Newton HJ, Seemann T, Harrison PF, Holmes NE, Rhee HW, Hong JI, Hartland EL, Stinear TP, Howden BP. Gao W, et al. Among authors: howden bp. PLoS Pathog. 2010 Jun 10;6(6):e1000944. doi: 10.1371/journal.ppat.1000944. PLoS Pathog. 2010. PMID: 20548948 Free PMC article.

8

Complete genome sequence of Staphylococcus aureus strain JKD6008, an ST239 clone of methicillin-resistant Staphylococcus aureus with intermediate-level vancomycin resistance.

Howden BP, Seemann T, Harrison PF, McEvoy CR, Stanton JA, Rand CJ, Mason CW, Jensen SO, Firth N, Davies JK, Johnson PD, Stinear TP. Howden BP, et al. J Bacteriol. 2010 Nov;192(21):5848-9. doi: 10.1128/JB.00951-10. Epub 2010 Aug 27. J Bacteriol. 2010. PMID: 20802046 Free PMC article.

9

Antimicrobial resistance: Not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA - its evolving antimicrobial resistance and implications for therapy.

Chua K, Laurent F, Coombs G, Grayson ML, Howden BP. Chua K, et al. Among authors: howden bp. Clin Infect Dis. 2011 Jan 1;52(1):99-114. doi: 10.1093/cid/ciq067. Clin Infect Dis. 2011. PMID: 21148528 Review.

10

Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.

Kelley PG, Gao W, Ward PB, Howden BP. Kelley PG, et al. Among authors: howden bp. J Antimicrob Chemother. 2011 May;66(5):1057-60. doi: 10.1093/jac/dkr066. Epub 2011 Mar 2. J Antimicrob Chemother. 2011. PMID: 21393156

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

333 results

Search Page